{"success":true,"data":{"pressRelease":{"id":"39851","rtpr_id":"nGNX2WvrB9","ticker":"KURA","exchange":"NASDAQ","all_tickers":["KURA"],"title":"Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit","author":"Globe Newswire","published_at":"2026-05-19T20:02:00.113Z","article_body":"SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA)\ntoday announced its participation in the TD Cowen 7(th) Annual Oncology\nInnovation Summit: Insights for ASCO & EHA. Kura management is scheduled to\nparticipate in a virtual fireside chat at 1:30 p.m. ET / 10:30 a.m. PT on May\n26, 2026.\n\nThe live webcast and archived replay of the event may be accessed on the\nInvestors section of the Company’s website at www.kuraoncology.com.\n\nAbout Kura Oncology\n\nKura Oncology is a biopharmaceutical company committed to realizing the\npromise of precision medicines for the treatment of cancer. Kura’s pipeline\nof small molecule drug candidates is designed to target cancer signaling\npathways and address high-need hematologic malignancies and solid tumors. Kura\ndeveloped and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved\nonce-daily, oral menin inhibitor for the treatment of adults with relapsed or\nrefractory NPM1-mutated acute myeloid leukemia, and continues to pioneer\nadvancements in menin inhibition and farnesyl transferase inhibition. For\nadditional information, please visit the Kura website\nat https://kuraoncology.com/ and follow us on X\n(https://www.globenewswire.com/Tracker?data=3YFqhJeCduoscl2Odfm__B5HnNpNacUBaEC5vwEL542SRJPrNDfGz7CB-XNNYz0Ro4QZFUjqaUblP5PeE1d4ZMPT7Uj7FSFq5-5avDqbgBjVSfkkRlyljPsrgTUSQTWEStpT0qKLJSpxPle6Akvb1IVjQLYBRO7v0afVtf6J9ju-kATkp5MLg3NgCJsKi2u5jyWYtFKcyaL3aAieX1ohhA==) and LinkedIn\n(https://www.globenewswire.com/Tracker?data=i_s-KLjmqVm34D07xLM25Y-puxu6rT97B6RSQLcGnHc7niSXfykXSKebxnNTOSUMfgeH2WqZesjP-cYkKmUMmNihVNk6gGuvsijZvIjxw2TmaOuwgVXwcm6FVFpJduD9DTCCtYVuDfMEN0Ko5VcjzieNjrbAJhKc6k8dSLsbKPX3M2rvLYKJ5JHG0Ap9w1gvGthixvxknXOZpIJMzubPECyTc8bEU-wUx3uCiyb_hMPUKK5OBvHPN2rYE0ugdIbvQHsoUukzwVRJmZZ6WSsl4w==).\n\nKura Contact\n\nGreg Mann (Investors and Media)\n858-987-4046\ngmann@kuraoncology.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ebf510d7-3727-4cc8-894f-6ce2d82b941a)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2WvrB9","title":"Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit","author":"Globe Newswire","ticker":"KURA","created":"2026-05-19T20:02:00.113Z","tickers":["KURA"],"exchange":"NASDAQ","article_body":"SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA)\ntoday announced its participation in the TD Cowen 7(th) Annual Oncology\nInnovation Summit: Insights for ASCO & EHA. Kura management is scheduled to\nparticipate in a virtual fireside chat at 1:30 p.m. ET / 10:30 a.m. PT on May\n26, 2026.\n\nThe live webcast and archived replay of the event may be accessed on the\nInvestors section of the Company’s website at www.kuraoncology.com.\n\nAbout Kura Oncology\n\nKura Oncology is a biopharmaceutical company committed to realizing the\npromise of precision medicines for the treatment of cancer. Kura’s pipeline\nof small molecule drug candidates is designed to target cancer signaling\npathways and address high-need hematologic malignancies and solid tumors. Kura\ndeveloped and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved\nonce-daily, oral menin inhibitor for the treatment of adults with relapsed or\nrefractory NPM1-mutated acute myeloid leukemia, and continues to pioneer\nadvancements in menin inhibition and farnesyl transferase inhibition. For\nadditional information, please visit the Kura website\nat https://kuraoncology.com/ and follow us on X\n(https://www.globenewswire.com/Tracker?data=3YFqhJeCduoscl2Odfm__B5HnNpNacUBaEC5vwEL542SRJPrNDfGz7CB-XNNYz0Ro4QZFUjqaUblP5PeE1d4ZMPT7Uj7FSFq5-5avDqbgBjVSfkkRlyljPsrgTUSQTWEStpT0qKLJSpxPle6Akvb1IVjQLYBRO7v0afVtf6J9ju-kATkp5MLg3NgCJsKi2u5jyWYtFKcyaL3aAieX1ohhA==) and LinkedIn\n(https://www.globenewswire.com/Tracker?data=i_s-KLjmqVm34D07xLM25Y-puxu6rT97B6RSQLcGnHc7niSXfykXSKebxnNTOSUMfgeH2WqZesjP-cYkKmUMmNihVNk6gGuvsijZvIjxw2TmaOuwgVXwcm6FVFpJduD9DTCCtYVuDfMEN0Ko5VcjzieNjrbAJhKc6k8dSLsbKPX3M2rvLYKJ5JHG0Ap9w1gvGthixvxknXOZpIJMzubPECyTc8bEU-wUx3uCiyb_hMPUKK5OBvHPN2rYE0ugdIbvQHsoUukzwVRJmZZ6WSsl4w==).\n\nKura Contact\n\nGreg Mann (Investors and Media)\n858-987-4046\ngmann@kuraoncology.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ebf510d7-3727-4cc8-894f-6ce2d82b941a)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-19T20:02:00.147245816Z","server_sent_at_ms":1779220920147},"received_at":"2026-05-19T20:02:00.239Z","source_url":null},"analysis":{"id":"29290","press_release_id":"39851","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Kura Oncology will participate in the TD Cowen 7th Annual Oncology Innovation Summit on May 26, 2026.\n\nManagement is scheduled for a virtual fireside chat at 1:30 p.m. ET.\n\nThe event is a standard investor relations appearance with no new data or strategic announcements disclosed in this release.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference appearance; no new catalysts disclosed."},"keyFigures":{},"quotedText":"Kura management is scheduled to participate in a virtual fireside chat at 1:30 p.m. ET / 10:30 a.m. PT on May 26, 2026.","namedEntities":{"people":[{"name":"Greg Mann","role":"Investors and Media Contact"}],"products":["KOMZIFTI","ziftomenib"],"companies":[{"name":"Kura Oncology, Inc.","ticker":"KURA"},{"name":"TD Cowen","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine conference participation announcement. No new clinical data, regulatory updates, or financial guidance disclosed. Standard investor relations activity."},"tickerRelevance":{"others":[],"primary":"KURA"},"globalImportance":15,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"conference_participation","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Kura Oncology will participate in the TD Cowen 7th Annual Oncology Innovation Summit on May 26, 2026.\n\nManagement is scheduled for a virtual fireside chat at 1:30 p.m. ET.\n\nThe event is a standard investor relations appearance with no new data or strategic announcements disclosed in this release.","key_figures":{},"named_entities":{"people":[{"name":"Greg Mann","role":"Investors and Media Contact"}],"products":["KOMZIFTI","ziftomenib"],"companies":[{"name":"Kura Oncology, Inc.","ticker":"KURA"},{"name":"TD Cowen","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-19T20:02:13.047Z","global_importance":15,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"conference_participation","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"durationMs":12800,"modelName":"george-droid-qwen-72b"}}